759456-76-3

Usage

Uses

Used in Pharmaceutical Synthesis:
4-Amino-1-ethanesulfonylpiperidine is used as a reactant in the synthesis of various pharmaceuticals and organic compounds. Its unique structure allows it to be a valuable building block in the creation of new and existing medications.
Used in Research and Development:
In the field of research and development, 4-Amino-1-ethanesulfonylpiperidine is employed for the exploration and creation of new drugs. Its chemical properties make it a promising candidate for further investigation into its potential therapeutic applications.
Used in Chemical Industry:
4-Amino-1-ethanesulfonylpiperidine is also utilized in the chemical industry for the production of various organic compounds. Its versatility in chemical reactions contributes to its value in this sector.
Safety Precautions:
Due to the potentially hazardous nature of 4-Amino-1-ethanesulfonylpiperidine, it is essential to handle this chemical with care. Proper safety measures, including the use of personal protective equipment and adherence to safety protocols, should be taken to minimize risks associated with its use.

Upstream product

• 73874-95-0 (piperidin-4-yl)carbamic acid tert-butyl ester 
• 594-44-5 Ethanesulfonyl chloride 
• 182223-54-7 piperidin-4-ylcarbamic acid benzyl ester 
• 651056-52-9 4-(tert-butoxycarbonyl)amino-1-ethanesulfonylpiperidine 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS

Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

SARS-COV-2 INHIBITORS HAVING COVALENT MODIFICATIONS FOR TREATING CORONAVIRUS INFECTIONS

Provided herein are compounds, pharmaceutical compositions and methods for treating a SARS-CoV-2 infection.

8-Substituted isoquinoline derivative and the use thereof

The present invention relates to a compound represented by the following formula (1): wherein D1, A1, D2, R1, D3, and R2 each have the same meaning as defined in the present specification or a salt thereof. The compound represented by the formula (1) or a salt thereof has an IKKβ inhibiting activity and the like and is useful for the prevention and/or treatment of IKKβ-associated diseases or symptoms and the like.

PYRAZOLE COMPOUNDS HAVING CANNABINOID RECEPTOR (CB1) ANTAGONIZING ACTIVITY

The present invention relates to a pyrazole compound having potent CB1-antagonizing activity, having the following formula [I]: wherein R1 and R2 are the same or different and an optionally substituted aryl group etc., R3 is an alkyl group etc., E is one of the following groups of the formula (i) to (iv): Q1 is a single bond, an alkylene group or a group of the formula: -N(R7)-, R7 is a hydrogen atom or an alkyl group, Q2 is a single bond, an oxygen atom or an alkylene group, R4 is a cycloalkyl group, a group of the formula: -N(R5)(R6) etc., one of R5 and R6 is a hydrogen atom or an alkyl group and the other is an alkyl group, a group of the formula: -N(R8)(R9) etc., D is an oxygen atom etc., RA1 is an amino group etc., RA2 is an optionally substituted aliphatic heterocyclic group, R is an alkyl group optionally substituted by one to three halogen atom(s) etc., one of R8 and R9 is a hydrogen atom or an alkyl group and the other is an alkyl group etc., or a pharmaceutically acceptable salt thereof.